Table 17Odds ratio of clinical response with preventive drugs, results from exploratory Bayesian network meta-analysis

ActiveSubjectsControl -- DivalproexControl -- PropranololControl -- Angiotensin Inhibiting DrugsControl -- NSAiDControl -- Beta BlockersControl -- AntidepressantsControl -- AntiepilepticsControl -- Ergot AlkaloidsControl -- ClonidineControl -- Ca ++
Blockers
Topiramate 16 RCTs1,8120.8
(0.4 to 1.4)
0.9
(0.5 to 1.4)
0.4
(0.2 to 1.1)
1.0
(0.5 to 1.9)
0.7
(0.4 to 1.2)
1.2
(0.6 to 2.0)
1.2
(0.7 to 2.0)
1.7
(0.6 to 4.2)
0.7
(0.3 to 1.3)
0.9
(0.4 to 2.7)
Divalproex 8 RCTs41911.1
(0.6 to 2.0)
0.6
(0.2 to 1.6)
1.3
(0.6 to 2.8)
1.0
(0.5 to 1.9)
1.5
(0.7 to 3.1)
1.5
(0.8 to 3.1)
2.2
(0.8 to 5.9)
0.9
(0.4 to 1.9)
1.2
(0.5 to 3.6)
Propranolol 24 RCTs1,1720.9
(0.5 to 1.5)
10.5
(0.2 to 1.2)
1.1
(0.6 to 2.2)
0.8
(0.5 to 1.3)
1.3
(0.8 to 2.3)
1.3
(0.8 to 2.4)
1.9
(0.7 to 4.8)
0.8
(0.4 to 1.4)
1.0
(0.4 to 2.9)
Angiotensin inhibiting drugs 5 RCTs1801.8
(0.6 to 5.2)
2.1
(0.8 to 5.2)
12.3
(0.8 to 6.6)
1.7
(0.7 to 4.6)
2.8
(1.0 to 7.5)
2.7
(1.0 to 7.5)
3.9
(1.2 to 13.8)
1.6
(0.6 to 4.5)
2.1
(0.7 to 8.2)
NSAID 9 RCTs11,4420.8
(0.4 to 1.7)
0.9
(0.5 to 1.7)
0.4
(0.2 to 1.2)
10.7
(0.4 to 1.4)
1.2
(0.6 to 2.5)
1.2
(0.6 to 2.6)
1.7
(0.6 to 4.6)
0.7
(0.3 to 1.6)
0.9
(0.3 to 2.9)
Beta blockers 17 RCTs7141.0
(0.5 to 2.0)
1.2
(0.7 to 1.9)
0.6
(0.2 to 1.5)
1.3
(0.7 to 2.6)
11.6
(0.9 to 2.9)
1.6
(0.9 to 3.1)
2.3
(0.9 to 5.9)
0.9
(0.5 to 1.7)
1.2
(0.5 to 3.6)
Antidepressants 10 RCTs5950.7
(0.3 to 1.4)
0.7
(0.4 to 1.3)
0.4
(0.1 to 1.0)
0.8
(0.4 to 1.8)
0.6
(0.3 to 1.2)
11.0
(0.5 to 2.0)
1.4
(0.5 to 3.8)
0.6
(0.3 to 1.2)
0.8
(0.3 to 2.3)
Antiepileptics 9 RCTs4570.7
(0.3 to 1.3)
0.8
(0.4 to 1.3)
0.4
(0.1 to 1.0)
0.9
(0.4 to 1.8)
0.6
(0.3 to 1.2)
1.0
(0.5 to 2.0)
11.4
(0.5 to 3.9)
0.6
(0.3 to 1.3)
0.8
(0.3 to 2.3)
Ergot alkaloids 2 RCTs2590.5
(0.2 to 1.3)
0.5
(0.2 to 1.4)
0.3
(0.1 to 0.9)
0.6
(0.2 to 1.7)
0.4
(0.2 to 1.2)
0.7
(0.3 to 1.9)
0.7
(0.3 to 2.0)
10.4
(0.1 to 1.2)
0.5
(0.2 to 2.1)
Clonidine 7 RCTs2711.1
(0.5 to 2.4)
1.3
(0.7 to 2.3)
0.6
(0.2 to 1.7)
1.4
(0.6 to 3.2)
1.1
(0.6 to 2.0)
1.7
(0.8 to 3.6)
1.7
(0.8 to 3.7)
2.4
(0.8 to 6.7)
11.3
(0.5 to 4.1)
Ca++ blockers 4 RCTs1360.9
(0.3 to 2.2)
1.0
(0.4 to 2.3)
0.5
(0.1 to 1.5)
1.1
(0.3 to 2.9)
0.8
(0.3 to 2.0)
1.3
(0.4 to 3.2)
1.3
(0.4 to 3.4)
1.8
(0.5 to 6.0)
0.8
(0.2 to 2.1)
1

NSAID = nonsteroidal anti-inflammatory drugs; RCT = randomized controlled trial

*

Clinical response (defined as ≥50 percent reduction in monthly episodic migraine frequency or self-reported substantial reduction in monthly migraine frequency Bold = differences are significant when 2.5 to 97.5% credible intervals of odds ratios do not include 1.

We used heterogeneous random effects model that assumes correlation within study (rho = 0.5) and heterogeneous between studies (WinBUG codes are in Appendix B) NSAID nonsteroidal anti-inflammatory drugs.

From: Results

Cover of Migraine in Adults: Preventive Pharmacologic Treatments
Migraine in Adults: Preventive Pharmacologic Treatments [Internet].
Comparative Effectiveness Reviews, No. 103.
Shamliyan TA, Kane RL, Taylor FR.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.